Question 1

What are the key takeaways from Bajaj Healthcare Limited?

Accepted Answer

Bajaj Healthcare Limited Q1 FY2027: Revenue ₹165.63 Cr (vs ₹148.84 Cr YoY), PAT ₹13.70 Cr (vs ₹11.83 Cr YoY) Bajaj Healthcare reported Q1 FY2027 revenue of ₹165.63 Cr and total income of ₹166.44 Cr, reflecting YoY top-line growth versus Q1 FY2026; profit after tax for the period was ₹13.70 Cr, up YoY from ₹11.83 Cr. EBITDA-like profit before exceptional items and tax was ₹16.46 Cr in Q1 FY2027, aided by stable gross margins despite higher finance and depreciation costs. The prior-quarter includ…

Question 2

What were Bajaj Healthcare Limited's key financial metrics?

Accepted Answer

Revenue from operations (Q1 FY2027): ₹165.63 Cr (16,563.17 lakhs) (vs ₹148.84 Cr in Q1 FY2026); Total income (Q1 FY2027): ₹166.44 Cr (16,644.31 lakhs) (vs ₹149.71 Cr in Q1 FY2026); Profit before tax (Q1 FY2027): ₹16.46 Cr (1,645.83 lakhs) (vs ₹14.53 Cr in Q1 FY2026); Profit / (loss) for the period (Q1 FY2027): ₹13.70 Cr (1,369.80 lakhs) (vs ₹11.83 Cr in Q1 FY2026)

Question 3

What were the highlights of Bajaj Healthcare Limited?

Accepted Answer

Q1 FY2027 revenue rose to ₹165.63 Cr from ₹148.84 Cr in Q1 FY2026, driven by higher sales in Pharmaceuticals. Profit before exceptional items and tax improved to ₹16.46 Cr in Q1 FY2027 versus ₹14.53 Cr in Q1 FY2026 indicating operational margin resilience. Exceptional reversal of ₹33.25 Cr was recorded in Q4 FY2026 which affects year-on-year comparability of profits. Cost of materials consumed in Q1 FY2027 was ₹91.59 Cr versus ₹69.88 Cr in Q1 FY2026, reflecting increased input spend.

Question 4

What is the outlook or guidance for Bajaj Healthcare Limited?

Accepted Answer

The Company obtained listing approvals from NSE and BSE for 20,79,409 equity shares during Q1 FY2027 which should improve free-float and liquidity. Unutilised proceeds from the preferential issue stood at ₹11.72 Cr as of 30 June 2026 available primarily for capex and strategic uses. Investment in capital expenditure allocation remains active with ₹23.31 Cr utilised out of a ₹35.00 Cr plan as of 30 June 2026, implying continued capex deployment.

Question 5

What are the key risks or concerns for Bajaj Healthcare Limited?

Accepted Answer

Regional instability in the Middle East led to reversal of previously recognised technical-knowhow income of ₹33.25 Cr recorded in Q4 FY2026, demonstrating concentration/credit risk on that customer. Higher input costs are visible with Cost of materials consumed at ₹91.59 Cr in Q1 FY2027 which may pressure gross margins if not passed on. Rising finance costs to ₹6.09 Cr in Q1 FY2027 increase fixed financial burden relative to prior-year quarter.

Bajaj Healthcare Limited

Quarterly Results 17

Annual Reports 14

Concalls 6

Bajaj Healthcare Limited

Quarterly Results 17

Annual Reports 14

Concalls 6